- Q4 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptMar 06, 2024$2.52 (-17.78%)Earnings
- Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptNov 09, 2023$1.92Earnings
- Q2 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptAug 08, 2023$2.55 (+1.23%)Earnings
- Q1 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptMay 09, 2023$2.65 (+9.76%)Earnings
- Q4 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptMar 08, 2023$1.37 (-10.47%)Earnings
- Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Q3 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptNov 09, 2022$1.54 (-0.76%)Earnings
- Xeris Biopharma Holdings Inc XP-8121 Call TranscriptOct 20, 2022
- Q2 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptAug 10, 2022$1.92 (+11.66%)Earnings
- Q1 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptMay 11, 2022$1.64 (-9.77%)Earnings
- Q4 2021 Xeris Biopharma Holdings Inc Earnings Call TranscriptMar 10, 2022$2.67 (+15.77%)Earnings
- Q3 2021 Xeris Biopharma Holdings Inc Earnings Call TranscriptNov 10, 2021$1.99 (+1.02%)Earnings
Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference Transcript
Good afternoon, everybody of you have to hope you had a great day for at the JPMorgan Health. I'm Bhavana Balakrishnan and associate here at the Healthcare Investment Banking team. Thank you so much for joining the presentation of the Xeris Biopharma. With us today, we have Paul Edick, who is the Chairman and Chief Executive Officer; and Allison Wey, SVP of IR and Corporate Communications. We'll leave time at the end for questions. But for now, over to you, Paul.
Thank you. I appreciate it. And welcome. Good to see everybody today, and thank you to JPMorgan for having us. I'm going to go through our presentation today and we'll save some time for questions. We are a public company. Please pay attention to our forward-looking statements if you take a time to read that we appreciate it.
Xeris is an emerging biopharma company. We're a self-sustaining, growth-oriented business committed to making a difference to patients. I'm going
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)